NightHawk Biosciences, Inc., (NHWK): Price and Financial Metrics

NightHawk Biosciences, Inc., (NHWK): $0.41

0.03 (+8.96%)

POWR Rating

Component Grades








Add NHWK to Watchlist
Sign Up

Industry: Biotech




#187 of 387

in industry

NHWK Price/Volume Stats

Current price $0.41 52-week high $1.16
Prev. close $0.38 52-week low $0.26
Day low $0.37 Volume 173,100
Day high $0.43 Avg. volume 97,242
50-day MA $0.38 Dividend yield N/A
200-day MA $0.55 Market Cap 10.78M

NHWK Stock Price Chart Interactive Chart >

NHWK Stock Summary

  • NHWK has a higher market value than just 5.83% of US stocks; more precisely, its current market capitalization is $10,954,394.
  • As for revenue growth, note that NHWK's revenue has grown -67.81% over the past 12 months; that beats the revenue growth of merely 3.08% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NHWK comes in at 25.35% -- higher than that of 93.05% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NIGHTHAWK BIOSCIENCES INC are FCEL, ADTN, ASXC, NWBO, and OMIC.
  • Visit NHWK's SEC page to see the company's official filings. To visit the company's web site, go to

NHWK Valuation Summary

  • In comparison to the median Healthcare stock, NHWK's price/sales ratio is 136.36% higher, now standing at 5.2.
  • NHWK's price/earnings ratio has moved up 10 over the prior 126 months.

Below are key valuation metrics over time for NHWK.

Stock Date P/S P/B P/E EV/EBIT
NHWK 2023-12-29 5.2 0.3 -0.2 -0.4
NHWK 2023-12-28 5.7 0.4 -0.2 -0.4
NHWK 2023-12-27 5.7 0.4 -0.2 -0.4
NHWK 2023-12-26 4.3 0.3 -0.2 -0.4
NHWK 2023-12-22 4.0 0.2 -0.2 -0.4
NHWK 2023-12-21 3.8 0.2 -0.2 -0.3

NHWK Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 84.6%.
  • The 4 year cash and equivalents growth rate now stands at 84.6%.
  • Its 3 year cash and equivalents growth rate is now at -18.93%.
Over the past 37 months, NHWK's revenue has gone up $3,808,228.

The table below shows NHWK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.916352 -9.248009 -44.8466
2022-06-30 1.378066 -28.55552 -39.27397
2022-03-31 1.786579 -43.49359 -35.65988
2021-12-31 2.112806 -38.12891 -35.07147
2021-09-30 2.102898 -33.18167 -27.95969
2021-06-30 2.451063 -22.94841 -29.37858

NightHawk Biosciences, Inc., (NHWK) Company Bio

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

NHWK Latest News Stream

Event/Time News Detail
Loading, please wait...

NHWK Latest Social Stream

Loading social stream, please wait...

View Full NHWK Social Stream

Latest NHWK News From Around the Web

Below are the latest news stories about NIGHTHAWK BIOSCIENCES INC that investors may wish to consider to help them evaluate NHWK as an investment opportunity.

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease CDMO services attracting considerable interest as state-of-the-art San Antonio facility helps address industry-wide scarcity for large molecule manufacturing DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announc

Yahoo | December 21, 2023

NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company

Manufacturing run at Scorpius’ state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing Advances multi-million dollar biomanufacturing contract awarded earlier this year; set to expand upon client’s regulatory filing and start of commercial manufacturing DURHAM, N.C., Dec. 18, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announ

Yahoo | December 18, 2023

NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets

Over $20 million in signed manufacturing contracts which includepremier biotech/pharma companies and research institutes Elusys divestiture and R&D cuts expected to eliminate over $40 million in commitments and reduce operating expenses by more than $13 million per year DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) today (“NightHawk” or the “Company”) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing

Yahoo | December 12, 2023

NightHawk Biosciences Provides Q3 2023 Business Update

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023. Jeff Wolf, Chief Executive Officer of NightHawk, commented, “We are very pleased with the progress of our Scorpius San Antonio facility where operations

Yahoo | November 20, 2023

NHWK: 2Q:23 Results

By John Vandermosten, CFA NYSE:NHWK READ THE FULL NHWK RESEARCH REPORT NightHawk Biosciences, Inc. (NYSE:NHWK) reported 2Q:23 results in mid-August as presented in a press release and in the filing of its Form 10-Q . Since our previous update in May, it has been quiet; however, Scorpius has continued to generate revenues and is developing its process development activities. In April, the final

Yahoo | October 9, 2023

Read More 'NHWK' Stories Here

NHWK Price Returns

1-mo 20.06%
3-mo 7.61%
6-mo -33.29%
1-year -58.59%
3-year -95.08%
5-year -95.72%
YTD -6.88%
2023 -45.31%
2022 -73.52%
2021 -43.28%
2020 61.20%
2019 -51.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!